After moving 3.7% during today's afternoon session, Glaukos is now trading at a price of $67.2 per share. On average, analysts give it a target price of $60.56.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Potential Glaukos Investors Should Analyze the Following:
-
Glaukos has moved 41.7% over the last year.
-
The company has a price to earnings growth (PEG) ratio of -3.46. A number between 0 and 1 could mean that the market is undervaluing Glaukos's estimated growth potential
-
Its Price to Book (P/B) ratio is 6.34
Understanding Glaukos's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 282,862 | 316,196 | -36.17 | -69.18 |
| 2021-12-31 | 294,011 | 290,256 | -21.38 | 61.07 |
| 2020-12-31 | 224,959 | 256,793 | -54.92 | -158.81 |
| 2019-12-31 | 236,984 | 248,688 | -21.22 | n/a |
Averaging out to -33.4% over the last 4 years, Glaukos's operating margins also have a high coefficient of variability, which stands at 47.7%. The firm's margins are declining at a -14.3% compounded yearly rate.
